呼吸门控碳离子扫描调强放疗同步整合加量治疗胰腺癌的剂量递增研究:基于四维CT的模拟
本研究利用12例胰腺癌患者的四维CT数据,模拟呼吸门控碳离子笔束扫描同步整合加量放疗的剂量分布。结果显示CTV2的D95%从55.2 Gy(RBE)计划剂量下的50.3±5.1 Gy(RBE)提升至67.2 Gy(RBE)计划剂量下的62.5±3.5 Gy(RBE),且危及器官剂量未受到与肿瘤剂量同等程度的影响;12例中4例肿瘤与胃肠道间距≥5 mm的患者在各剂量水平下CTV2 D95%均≥95%计划剂量。
要点
- 呼吸门控碳离子笔束扫描同步整合加量可使胰腺癌CTV2 D95%从50.3±5.1 Gy(RBE)提升至62.5±3.5 Gy(RBE)。
- 肿瘤与胃肠道间距≥5 mm的4例患者在各剂量水平下CTV2 D95%均≥95%计划剂量。
- 危及器官剂量未受到与肿瘤剂量同等程度的影响。
核心结论
- 呼吸门控碳离子笔束扫描同步整合加量可在不影响危及器官剂量的同等程度下实现胰腺癌剂量递增,结果提示该剂量递增方案可行,但需在临床试验中确认。
研究设计与样本
- 模拟研究,使用12例胰腺癌患者的四维CT数据,勾画大体肿瘤体积和两个临床靶体积,考虑束流射程分次内不确定度计算野特异性靶体积并生成两个计划靶体积;PTV1计划剂量为55.2 Gy(RBE)分12次,PTV2同步整合加量至67.2 Gy(RBE);对靶区和危及器官进行剂量评估。
诊断标准与关键数值
- PTV1计划剂量55.2 Gy(RBE)分12次,PTV2同步整合加量计划剂量至67.2 Gy(RBE)。
- CTV2 D95%从计划剂量55.2 Gy(RBE)时的50.3±5.1 Gy(RBE)增至计划剂量67.2 Gy(RBE)时的62.5±3.5 Gy(RBE)。
- 12例中4例肿瘤与胃肠道间距≥5 mm的患者,在各剂量水平下CTV2 D95%均≥95%计划剂量。
临床应用与阅片要点
- 作者认为呼吸门控碳离子笔束扫描同步整合加量治疗胰腺癌的剂量递增可行,但需在临床试验中确认。
局限性
- 原文结论指出该剂量递增方案的可行性需在临床试验中确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Pancreatic cancer is a difficult to treat disease with a persistently high mortality rate. We evaluated dose distribution simulation with respiratory-gated carbon-ion pencil beam scanning (C-PBS) with a simultaneous integrated boost (SIB) to increase tumour dose, sparing organs at risk (OARs).
METHODS: Using four-dimensional CT data of 12 patients, we delineated gross tumour volume and two clinical target volumes (CTVs). To consider beam range intrafractional uncertainty, we calculated field-specific target volumes, from which two planning target volumes (PTVs) were generated. PTV1 would receive a planned dose of 55.2 Gy [relative biological effectiveness (RBE)-weighted absorbed dose] in 12 fractions, and PTV2 would receive an SIB dose up to 67.2 Gy (RBE). Dose assessments were conducted with regard to the targets and OARs.
RESULTS: CTV2 dose covering 95% of the volume (D95%) increased from 50.3 ± 5.1 Gy (RBE) to 62.5 ± 3.5 Gy (RBE) for a planned dose from 55.2 Gy (RBE) to 67.2 Gy (RBE). For 4 of 12 patients with a distance of ≥5 mm between the tumour and the gastrointestinal tract, CTV2 D95% was ≥95% of planned dose at all dose levels.
CONCLUSION: We quantified dose escalation with respiratory-gated C-PBS using SIB for pancreatic cancer and revealed that OAR dose was not affected to the same degree as the tumour dose. Advances in knowledge: A simulation study on respiratory-gated C-PBS with SIB for pancreatic cancer was performed. The results indicated the feasibility of dose escalation for pancreatic cancer, which should be confirmed in clinical trials.
引用
- Kawashiro S, Mori S, Yamada S, et al. Dose escalation study with respiratory-gated carbon-ion scanning radiotherapy using a simultaneous integrated boost for pancreatic cancer: simulation with four-dimensional computed tomography. Br J Radiol. 2017. PMID: 28181819. doi:10.1259/bjr.20160790
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。